NCAM1 and metastatic colorectal cancer: A significant decrease in the percentage of CD56+ and CD16+CD56+ lymphocytes was determined in the patients with metastatic colorectal cancer before the initiation of cetuximab-based therapy, when compared with healthy control individuals (Table 1).